Answers are grounded in this paper and cite their sources.
Acute lower respiratory tract infection (LRTI), also referred to as ‘acute bronchitis’ and ‘acute chest infection’, remains one of the most common presentations to primary care internationally.1 Usually defined as an acute cough with at least one of the following, sputum, chest pain, shortness of breath, and/or wheeze,2 between 52% and 100% (median 88%) of patients are currently prescribed an antibiotic.3 Using conservative national morbidity survey estimates,1 LRTI costs the UK NHS an estimated £190 million annually.4 Despite good evidence that antibiotics do not reduce the duration or severity of LRTI,5 they continue to be widely prescribed3 promoting bacterial resistance to antibiotics.6 Between 2002 and 2010, the total number of antibiotics dispensed per 1000 population in England increased by an alarming 25%,7 a statistic that cannot be explained by increasing primary care presentations: consultations for upper and lower RTIs fell by 19% in the same period.8 So why is our antibiotic prescribing increasing? There is evidence that a key concern is avoiding under-treatment.9 None of us wants to be seen to have withheld treatment from a patient who subsequently deteriorates, especially if they are hospitalised. Although rare, it damages doctor–patient relationships, and leads to complaints and medico-legal consequences. However, the rising use of antibiotics and antimicrobial resistance is also of concern, and is now at the top of the Chief Medical Officer (CMO) for England, the Department of Health and the National Institute for Health Research (NIHR) agendas. In March 2013, the CMO highlighted the rise of antimicrobial resistance as a threat to healthcare delivery,10 in August 2013 the NIHR …
No takes yet. Share an insight, caveat, or question.
Hay et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: